NEO vs. EVO, BEAM, CPRX, AMPH, AGIO, BTSG, KROS, SANA, NVAX, and GLPG
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Evotec (EVO), Beam Therapeutics (BEAM), Catalyst Pharmaceuticals (CPRX), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), BrightSpring Health Services (BTSG), Keros Therapeutics (KROS), Sana Biotechnology (SANA), Novavax (NVAX), and Galapagos (GLPG). These companies are all part of the "medical" sector.
Evotec (NASDAQ:EVO) and NeoGenomics (NASDAQ:NEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
5.8% of Evotec shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Comparatively, 1.3% of NeoGenomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NeoGenomics received 493 more outperform votes than Evotec when rated by MarketBeat users. However, 75.00% of users gave Evotec an outperform vote while only 70.66% of users gave NeoGenomics an outperform vote.
In the previous week, Evotec had 1 more articles in the media than NeoGenomics. MarketBeat recorded 4 mentions for Evotec and 3 mentions for NeoGenomics. Evotec's average media sentiment score of 0.90 beat NeoGenomics' score of 0.64 indicating that NeoGenomics is being referred to more favorably in the news media.
Evotec presently has a consensus price target of $11.00, suggesting a potential upside of 109.52%. NeoGenomics has a consensus price target of $19.78, suggesting a potential upside of 33.63%. Given NeoGenomics' stronger consensus rating and higher possible upside, equities analysts clearly believe Evotec is more favorable than NeoGenomics.
NeoGenomics has lower revenue, but higher earnings than Evotec.
Evotec has a net margin of 0.00% compared to Evotec's net margin of -13.79%. NeoGenomics' return on equity of 0.00% beat Evotec's return on equity.
Evotec has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Summary
Evotec beats NeoGenomics on 9 of the 16 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
